CN115032188A - A kind of detection method of serum glycated albumin - Google Patents
A kind of detection method of serum glycated albumin Download PDFInfo
- Publication number
- CN115032188A CN115032188A CN202210640591.3A CN202210640591A CN115032188A CN 115032188 A CN115032188 A CN 115032188A CN 202210640591 A CN202210640591 A CN 202210640591A CN 115032188 A CN115032188 A CN 115032188A
- Authority
- CN
- China
- Prior art keywords
- reagent
- detection method
- absorbance
- glycated albumin
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Plasma & Fusion (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及医学技术领域,尤其涉及一种血清糖化白蛋白的检测方法。The invention relates to the technical field of medicine, in particular to a detection method for serum glycated albumin.
背景技术Background technique
当前的临床生化检测,二甲以上医疗机构检验科设备多为进口品牌,常规检测为主。POCT属于IVD细分市场,对于二甲以下基层医院,检验科样本量少,技术水平相对较低,大型设备的实用性差,因此检验科通常使用POCT产品替代传统检验方法来诊断。常规的生化检测方法中,液体生化往往较干式生化测试的精密度好、准确性高,因此对于这类POCT检测产品,液体生化检测仍有较大的应用市场。For the current clinical biochemical testing, most of the laboratory equipment in medical institutions above the second grade are imported brands, and routine testing is the mainstay. POCT belongs to the IVD market segment. For primary hospitals below the second grade, the laboratory department has a small sample size, relatively low technical level, and poor practicability of large-scale equipment. Therefore, the laboratory department usually uses POCT products instead of traditional inspection methods for diagnosis. Among conventional biochemical testing methods, liquid biochemical testing is often more precise and accurate than dry biochemical testing. Therefore, liquid biochemical testing still has a large application market for such POCT testing products.
由于POCT类产品的市场相对门槛较低,竞争尤为激烈,对于定量产品往往需要保证其出厂前的一次校准能保证产品在整个生命周期测试结果的准确性、可靠性。于液体生化试剂而言,其试剂的稳定性、准确性要求进一步提高。而对于采用终点法比色测定的一类试剂,往往在试剂开发中发现,其双试剂一经混合会发生较大的光吸收信号变化,且随着试剂保存时间延长,这种试剂空白背景信号的变化可能较初期更显著。该信号的变化可能产生如下两种影响:①空白背景信号过高,影响检测灵敏度。②长期保存过程中,因试剂空白背景信号发生升高或降低,导致计算的结果出现假性升高或假性下降现象,造成检测结果偏差。Due to the relatively low market threshold for POCT products, the competition is particularly fierce. For quantitative products, it is often necessary to ensure that a calibration before leaving the factory can ensure the accuracy and reliability of the test results throughout the life cycle of the product. For liquid biochemical reagents, the stability and accuracy of the reagents are required to be further improved. For a class of reagents that use end-point colorimetric determination, it is often found in the development of reagents that once the two reagents are mixed, a large change in the light absorption signal will occur, and with the prolongation of the reagent storage time, the blank background signal of this reagent will be reduced. Changes may be more pronounced than initially. The change of this signal may have the following two effects: ① The blank background signal is too high, which affects the detection sensitivity. ②During long-term storage, due to the increase or decrease of the blank background signal of the reagent, the calculated result will appear falsely increased or falsely decreased, resulting in the deviation of the detection result.
在糖化白蛋白的酶法测定试剂盒中,多数先采用R1试剂中的蛋白酶对糖化白蛋白进行酶切水解成糖化氨基酸或糖化多肽,测定第一吸光度;再加入R2试剂中的果糖氨基酸氧化酶/果糖基态氧化酶、过氧化物酶偶联反应,经由Trinder反应显色,在平衡终点测定第二吸光度,计算两个吸光度差值。经由吸光度-浓度校正曲线,测得样本中糖化白蛋白浓度。反应过程如下:In the enzymatic assay kits for glycated albumin, most of them firstly use the protease in the R1 reagent to digest and hydrolyze the glycated albumin into glycated amino acids or glycated polypeptides, and measure the first absorbance; then add the fructose amino acid oxidase in the R2 reagent. /Fructose ground state oxidase, peroxidase coupling reaction, color development through Trinder reaction, measure the second absorbance at the equilibrium end point, and calculate the difference between the two absorbances. The concentration of glycated albumin in the sample was determined via an absorbance-concentration calibration curve. The reaction process is as follows:
此测定方法中,出现试剂空白反应度高,且主要发生在双试剂混合的瞬间。分析其原因,主要有以下两点:其一,为了使糖化白蛋白的分解反应更好得达到终点,一般试剂中蛋白酶用量足够高,且蛋白酶在第一段时间的孵育反应中,酶活性被充分激活或已达到较高水平,当加入第二试剂后很可能使试剂中含有的其他蛋白类成分被酶切消化产生不溶因子或特定波长下光吸收;其二,Trinder反应的有效成分(如4-氨基安替比林和酚/胺类物质、过氧化物酶)混合时产生快速显色,造成背景升高。In this assay method, the reagent blank has a high degree of reactivity, and it mainly occurs at the moment when the two reagents are mixed. To analyze the reasons, there are mainly the following two points: First, in order to make the decomposition reaction of glycated albumin better to reach the end point, the amount of protease in the general reagent is high enough, and the enzyme activity of the protease is reduced during the incubation reaction of the first period of time. It is fully activated or has reached a high level. When the second reagent is added, it is likely that other protein components contained in the reagent will be digested by enzyme digestion to produce insoluble factors or light absorption at specific wavelengths; second, the active components of Trinder reaction (such as 4-Aminoantipyrine produces rapid color development when mixed with phenol/amines, peroxidase, resulting in increased background.
发明内容SUMMARY OF THE INVENTION
有鉴于此,本发明提供了一种血清糖化白蛋白的检测方法。该试剂盒和检测方法有效地降低了试剂空白背景高的测定干扰,同时降低了样本中内源性糖化氨基酸的干扰,极大提升了糖化白蛋白检测试剂盒的测试准确性,并消除了因长效期保存过程中可能出现的试剂空白背景变化导致的测试结果偏差。In view of this, the present invention provides a detection method for serum glycated albumin. The kit and detection method effectively reduce the determination interference caused by the high blank background of the reagent, and at the same time reduce the interference of endogenous glycated amino acids in the sample, greatly improve the test accuracy of the glycated albumin detection kit, and eliminate the Deviation of test results caused by changes in reagent blank background that may occur during long-term storage.
为了实现上述发明目的,本发明提供以下技术方案:In order to achieve the above-mentioned purpose of the invention, the present invention provides the following technical solutions:
一种血清糖化白蛋白的检测方法,包括:A detection method for serum glycated albumin, comprising:
取试剂1,加入待测样本或校准品,孵育第一时长;再加入试剂2,混匀并在预定时间测定第一吸光度值A1;再孵育第二时长,测定第二吸光度值A2;计算扣除空白背景信号后的吸光度变化值ΔA=A2-A1,以吸光度变化值ΔA计算血清糖化白蛋白浓度;Take
其中,所述试剂1包括果糖氨基酸氧化酶和过氧化物酶;所述试剂2包括蛋白酶。Wherein, the
本发明中,以吸光度变化值ΔA计算血清糖化白蛋白浓度,具体为:In the present invention, the serum glycated albumin concentration is calculated by the absorbance change value ΔA, specifically:
将吸光度变化值ΔA代入血清糖化白蛋白标准计算函数中计算出血清糖化白蛋白浓度。The concentration of serum glycated albumin was calculated by substituting the absorbance change value ΔA into the standard calculation function of serum glycated albumin.
本发明中,所述血清糖化白蛋白标准计算函数由以下方法确定:In the present invention, the serum glycated albumin standard calculation function is determined by the following method:
建立不同校准品浓度C与相应吸光度变化值ΔA的函数关系,获得标准计算函数。Establish the functional relationship between the concentration C of different calibrators and the corresponding absorbance change value ΔA, and obtain the standard calculation function.
本发明中,取试剂1,加入待测样本或校准品,孵育第一时长;加入试剂2,混匀并在预定时间测定第一吸光度值A1。其中,所述预定时间具体为:在加入试剂2并混匀之后开始计时的0-20s,优选为0~18s。即第一吸光度值A1的测定是在加入试剂2并混匀之后的20s内进行,可以是混匀之后立即进行测定(即0s),也可以在0~20s之间任意一个时间点进行测定。In the present invention, the
本发明中,所述第一时长和第二时长均选自3~5分钟中的任一时长,具体可为3min、4min或5min。In the present invention, the first duration and the second duration are both selected from any duration of 3 to 5 minutes, specifically 3 min, 4 min or 5 min.
本发明中,第一吸光度值和第二吸光度值检测的波长均为500-600nm,具体可为500nm、550nm或600nm。In the present invention, the wavelengths for detecting the first absorbance value and the second absorbance value are both 500-600 nm, specifically 500 nm, 550 nm or 600 nm.
为了解决由于双试剂混合造成空白背景信号变化过大的干扰问题,申请人尝试了不同的方法,如:将第一吸光度的测定由加入R2试剂之前的第一段孵育终点改为加入R2试剂之后的快速测定,再经过第二段孵育反应测定第二吸光度。但是研究发现,由于第一步孵育结束后,蛋白酶已将糖化白蛋白大部分转化为糖化氨基酸或糖化多肽中间产物,一旦加入含果糖氨基酸氧化酶或果糖基态氧化酶、过氧化物酶的R2试剂后,反应极快速发生(即反应度急剧上升),并很快达到平衡终点,此时采集第一吸光度的时间无论多靠近加入R2试剂的时间点,该吸光度变化并非简单的试剂空白吸光度,实际叠加了样本参与反应的信号变化,此时更容易发生不同浓度样本的反应信号测试偏差。In order to solve the problem of excessive interference of the blank background signal caused by the mixing of the two reagents, the applicant tried different methods, such as: changing the measurement of the first absorbance from the end point of the first incubation period before adding the R2 reagent to after adding the R2 reagent The rapid determination, and then through the second incubation reaction to measure the second absorbance. However, the study found that after the first step of incubation, the protease has converted most of the glycated albumin into glycated amino acids or glycated polypeptide intermediates. Once the R2 reagent containing fructose amino acid oxidase or fructose ground state oxidase and peroxidase is added After the reaction, the reaction occurs very quickly (that is, the degree of reactivity rises sharply), and the equilibrium end point is quickly reached. At this time, no matter how close the time of collecting the first absorbance is to the time point of adding the R2 reagent, the absorbance change is not a simple reagent blank absorbance. The signal changes of the samples participating in the reaction are superimposed, and the reaction signal test deviation of samples with different concentrations is more likely to occur at this time.
申请人经过长期研究、摸索,最终通过对传统的糖化血红蛋白检测试剂盒的组分进行了重新搭配,并于特定的时间节点检测空白背景信号,有效地降低了试剂空白背景高的测定干扰。该方法调换了蛋白酶与果糖氨基酸氧化酶(FAOD)、过氧化物酶(POD)的位置,将果糖氨基酸氧化酶(FAOD)、过氧化物酶(POD)放置于试剂1中,将蛋白酶放置于试剂2中,一方面,本发明调整组分之后的试剂盒利用果糖氨基酸氧化酶或果糖基态氧化酶有效地消除了样本中糖化氨基酸的内源性干扰。另一方面,初期催化反应启动慢,糖化白蛋白转化为糖化氨基酸或糖化多肽中间产物的程度很低,故这段延迟反应留足了足够的时间供第一吸光度的采集(A1),该吸光度可较准确的反应实时的试剂空白背景信号,此后在第二段孵育平衡终点再采集第二吸光度(A2),计算所得的对应样本浓度下的吸光度变化ΔA(A2-A1)即为准确扣除了实时试剂空白背景吸光度的测定信号。因此,采用本发明试剂盒进行检测既减少了试剂空白背景高的测定干扰,又降低了样本中内源性糖化氨基酸的干扰,极大提升了糖化白蛋白检测试剂盒的测试准确性,并消除了因长效期保存过程中可能出现的试剂空白背景变化导致的测试结果偏差。After long-term research and exploration, the applicant finally recombined the components of the traditional glycosylated hemoglobin detection kit, and detected the blank background signal at a specific time point, effectively reducing the detection interference due to the high blank background of the reagent. In this method, the positions of protease, fructose amino acid oxidase (FAOD) and peroxidase (POD) are exchanged, and fructose amino acid oxidase (FAOD) and peroxidase (POD) are placed in
本发明中,对于试剂盒中试剂1和试剂2的其他组分,比如抗干扰剂、缓冲液、防腐剂、稳定剂等的种类和用量都不作具体限定,本领域技术人员按照需要和实际情况常规选择即可。本发明中,所述试剂1包括缓冲液、果糖氨基酸氧化酶、过氧化物酶、N-乙基-N-(2-羟基-3-磺丙基)-3-甲基苯胺钠盐(TOOS)、抗干扰剂、防腐剂和稳定剂;试剂2包括缓冲液、蛋白酶K、4-氨基安替比林、防腐剂和稳定剂。In the present invention, the types and amounts of other components of
进一步地,本发明中,所述试剂1包括:Further, in the present invention, the
所述试剂2包括:The reagent 2 includes:
一些实施方案中,所述缓冲液为三羟甲基氨基甲烷盐酸盐(Tris-HCl)、3-(N-吗啡啉)丙磺酸(MOPS)、4-羟乙基哌嗪乙磺酸(HEPES)、哌嗪-1,4-二羟基丙磺酸(POPSO)、3-(N-吗啉基)-2-羟基丙磺酸(MOPSO)中的至少一种。In some embodiments, the buffer is tris-hydroxymethylaminomethane hydrochloride (Tris-HCl), 3-(N-morpholine)propanesulfonic acid (MOPS), 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), at least one of piperazine-1,4-dihydroxypropanesulfonic acid (POPSO), and 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO).
一些实施方案中,所述防腐剂为叠氮钠和/或Proclin 30。In some embodiments, the preservative is sodium azide and/or Proclin 30.
本发明中,抗干扰剂的目的是为了去除样本中的干扰物质,如抗坏血酸、或胆红素等。一些实施方案中,所述抗干扰剂为抗坏血酸氧化酶或胆红素氧化酶。In the present invention, the purpose of the anti-interference agent is to remove interfering substances in the sample, such as ascorbic acid or bilirubin. In some embodiments, the anti-interfering agent is ascorbate oxidase or bilirubin oxidase.
一些实施方案中,所述稳定剂为水溶性钙盐、甘油、海藻糖、蔗糖、牛血清白蛋白、乙二胺四乙酸二钠中的一种或几种。In some embodiments, the stabilizer is one or more of water-soluble calcium salts, glycerol, trehalose, sucrose, bovine serum albumin, and disodium EDTA.
一些具体实施例中,所述试剂盒中,试剂1组成如下:In some specific embodiments, in the kit, the
试剂2组成如下:Reagent 2 is composed as follows:
一些实施方案中,步骤1中所述孵育和再孵育的时间为3~5分钟。In some embodiments, the time of incubation and re-incubation in
一些实施方案中,步骤1中所述第一吸光度值的测定在加入试剂2混匀之后立即(18s内)进行。In some embodiments, the determination of the first absorbance value in
本发明对传统试剂盒的组分进行了重新搭配、组合,于特定的时间节点检测空白背景信号,有效地降低了试剂空白背景高的测定干扰,并降低了样本中内源性糖化氨基酸的干扰,极大提升了糖化白蛋白检测试剂盒的测试准确性,并消除了因长效期保存过程中可能出现的试剂空白背景变化导致的测试结果偏差。The invention recombines and combines the components of the traditional kit, detects the blank background signal at a specific time node, effectively reduces the determination interference of the high blank background of the reagent, and reduces the interference of endogenous glycosylated amino acids in the sample , which greatly improves the test accuracy of the glycated albumin detection kit, and eliminates the test result deviation caused by the blank background change of the reagent that may occur during the long-term storage process.
附图说明Description of drawings
图1示对比例1试剂空白背景吸光度测定曲线;Fig. 1 shows the determination curve of the blank background absorbance of the reagent of Comparative Example 1;
图2示对比例1线性下限浓度的样本吸光度测定曲线;Fig. 2 shows the sample absorbance measurement curve of the linear lower limit concentration of Comparative Example 1;
图3示对比例1线性上限浓度的样本吸光度测定曲线;Fig. 3 shows the sample absorbance measurement curve of the linear upper limit concentration of Comparative Example 1;
图4示实施例1试剂空白背景吸光度测定曲线;Figure 4 shows the reagent blank background absorbance measurement curve of Example 1;
图5示实施例1线性下限浓度的样本吸光度测定曲线;Fig. 5 shows the sample absorbance measurement curve of the linear lower limit concentration of Example 1;
图6示实施例1线性上限浓度的样本吸光度测定曲线。6 shows the sample absorbance measurement curve of the linear upper limit concentration of Example 1.
具体实施方式Detailed ways
本发明提供了一种血清糖化白蛋白的检测方法。本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。The invention provides a detection method for serum glycated albumin. Those skilled in the art can learn from the content of this document and appropriately improve the process parameters to achieve. It should be particularly pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are deemed to be included in the present invention. The method and application of the present invention have been described through the preferred embodiments, and it is obvious that relevant persons can make changes or appropriate changes and combinations of the methods and applications herein without departing from the content, spirit and scope of the present invention, so as to realize and apply the present invention. Invention technology.
如无特殊说明,本发明采用的试材皆为普通市售品,皆可于市场购得。Unless otherwise specified, the test materials used in the present invention are all common commercial products and can be purchased in the market.
下面结合实施例,进一步阐述本发明:Below in conjunction with embodiment, the present invention is further elaborated:
实施例1Example 1
1.配制如下组成的试剂1和试剂2。1. Prepare
试剂1组成:
试剂2组成:Reagent 2 composition:
2.检测参数:取150μL试剂1,加入10μL样本/校准品,孵育3~5min;再加入50μL试剂2,混匀,立即(18s内)测定546nm波长下的第一吸光度A1,孵育3~5min后记录第二吸光度值A2。2. Detection parameters: take 150 μL of
对比例1Comparative Example 1
1.配制如下组成的试剂1和试剂2。1. Prepare
试剂1组成:
试剂2组成:Reagent 2 composition:
2、检测参数:取150μL试剂1,加入10μL样本/校准品,孵育3~5min,测定546nm波长下的第一吸光度A1;再加入50μL试剂2,混匀,孵育3~5min后测定第二吸光度值A2。2. Detection parameters: take 150 μL of
对比例2Comparative Example 2
配制如下组成的试剂1和试剂2。Prepare
试剂1组成:
试剂2组成:Reagent 2 composition:
2.检测参数:取150μL试剂1,加入10μL样本/校准品,孵育3~5min;再加入50μL试剂2,混匀,立即(18s内)测定546nm波长下的第一吸光度A1,孵育3~5min后测定第二吸光度值A2。2. Detection parameters: take 150 μL of
测试例test case
按照对比例1、对比例2、实施例1的试剂盒和检测方法进行检测,通过Trinder反应显色测定不同保存有效期下糖化白蛋白检测试剂的试剂空白吸光度、信号梯度、临床比对相关性,具体结果见表1和图1~6.Detected according to the kits and detection methods of Comparative Example 1, Comparative Example 2, and Example 1, and determined the reagent blank absorbance, signal gradient, and clinical comparison correlation of glycated albumin detection reagents under different shelf life by Trinder reaction color development, The specific results are shown in Table 1 and Figures 1-6.
表1Table 1
结果显示,对比例1有较大的试剂空白背景,且随试剂放置时间越长试剂空白信号呈明显上升,对只有一次校准的POCT类糖化白蛋白检测试剂盒来说,低值样本的准确性易受到极大影响。对比例2较对比例1有较小的试剂空白背景,但线性梯度显著变小,且临床相关性差。实施例1相较于对比例1和对比例2,其试剂空白背景更低(接近零的水平),临床相关性更好,其线性梯度也满足一般的检测要求。The results show that the comparative example 1 has a larger reagent blank background, and the reagent blank signal increases significantly with the longer the reagent is placed. For the POCT-like glycated albumin detection kit with only one calibration, the accuracy of the low-value samples easily affected. Comparative Example 2 had a smaller reagent blank background than Comparative Example 1, but the linear gradient was significantly smaller, and the clinical correlation was poor. Compared with Comparative Example 1 and Comparative Example 2, Example 1 has lower reagent blank background (close to zero level), better clinical correlation, and its linear gradient also meets general detection requirements.
以上仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above are only the preferred embodiments of the present invention. It should be pointed out that for those skilled in the art, some improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be regarded as It is the protection scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210640591.3A CN115032188A (en) | 2022-06-08 | 2022-06-08 | A kind of detection method of serum glycated albumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210640591.3A CN115032188A (en) | 2022-06-08 | 2022-06-08 | A kind of detection method of serum glycated albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115032188A true CN115032188A (en) | 2022-09-09 |
Family
ID=83122962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210640591.3A Pending CN115032188A (en) | 2022-06-08 | 2022-06-08 | A kind of detection method of serum glycated albumin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115032188A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006254918A (en) * | 2006-04-24 | 2006-09-28 | Asahi Kasei Pharma Kk | Method for measuring rate of glycated protein |
| CN101413027A (en) * | 2001-01-31 | 2009-04-22 | 旭化成制药株式会社 | Compositions for assaying glycoprotein |
| CN109239059A (en) * | 2018-08-30 | 2019-01-18 | 中拓生物有限公司 | A kind of glycated serum protein assay kit and its preparation method and application |
| CN109680036A (en) * | 2017-10-02 | 2019-04-26 | 爱科来株式会社 | The measurement of glycated proteins |
| CN111808921A (en) * | 2020-06-15 | 2020-10-23 | 武汉生之源生物科技股份有限公司 | Trinder reaction-based detection kit and application thereof |
| CN113884449A (en) * | 2020-07-03 | 2022-01-04 | 豪夫迈·罗氏有限公司 | Photometric interference determination |
-
2022
- 2022-06-08 CN CN202210640591.3A patent/CN115032188A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101413027A (en) * | 2001-01-31 | 2009-04-22 | 旭化成制药株式会社 | Compositions for assaying glycoprotein |
| JP2006254918A (en) * | 2006-04-24 | 2006-09-28 | Asahi Kasei Pharma Kk | Method for measuring rate of glycated protein |
| CN109680036A (en) * | 2017-10-02 | 2019-04-26 | 爱科来株式会社 | The measurement of glycated proteins |
| CN109239059A (en) * | 2018-08-30 | 2019-01-18 | 中拓生物有限公司 | A kind of glycated serum protein assay kit and its preparation method and application |
| CN111808921A (en) * | 2020-06-15 | 2020-10-23 | 武汉生之源生物科技股份有限公司 | Trinder reaction-based detection kit and application thereof |
| CN113884449A (en) * | 2020-07-03 | 2022-01-04 | 豪夫迈·罗氏有限公司 | Photometric interference determination |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11808777B2 (en) | Method of analyzing diluted biological sample component | |
| US5516700A (en) | Automated urinalysis method | |
| CN109239059B (en) | Glycated serum protein assay kit and preparation method and application thereof | |
| CN105388146B (en) | Kit that is a kind of while detecting sodium in urine, creatinine and microalbumin | |
| Liu et al. | Direct enzymatic assay for% HbA1c in human whole blood samples | |
| CN106124779A (en) | A kind of test kit for measuring creatinine and method | |
| CN111057150B (en) | Latex microsphere, application thereof and glycosylated hemoglobin detection kit | |
| CN105334211B (en) | It is a kind of while detect the kit of sodium and creatinine in urine | |
| CN108414767A (en) | Glycosylated hemoglobin assay kit | |
| Morin et al. | Single Glucose Oxidase—Peroxidase reagent for two-minute determination of serum glucose | |
| PL183162B1 (en) | Method of determining glycoproteins | |
| CN106290323A (en) | A kind of stable, uric acid reagent that capacity of resisting disturbance is strong and detection method | |
| CN106367472A (en) | Kit and method for determining uric acid | |
| CN112029817B (en) | Creatinine detection kit and application method thereof | |
| CN104198422B (en) | Composite stabilizer for alpha-hydroxybutyric dehydrogenase assay kit | |
| CN104673878B (en) | Kit for measuring concentration ratio of glycated albumin and albumin by virtue of single system | |
| CN112710854B (en) | Anti-interference and stable serum total bilirubin (enzyme method) determination kit and preparation method and application thereof | |
| CN112710853B (en) | Anti-interference and stable serum direct bilirubin (enzyme method) determination kit and preparation method and application thereof | |
| CN114441516A (en) | A kind of uric acid detection kit and preparation method thereof | |
| CN114200122A (en) | Freeze-dried reagent ball for uric acid detection, configuration method thereof and microfluidic detection chip | |
| CN115032188A (en) | A kind of detection method of serum glycated albumin | |
| CN113514451B (en) | Blood creatinine detection reagent ball and blood creatinine detection chip | |
| CN115267229A (en) | Kit and preparation method thereof | |
| CN110777190B (en) | Kit for detecting homocysteine and application thereof | |
| Randell et al. | An automated enzymatic method on the Roche COBAS MIRATM S for monitoring phenylalanine in dried blood spots of patients with phenylketonuria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |